RxDoctor Payments Data

Musa Awan, MD

Ophthalmology · Lakeland, FLNPI 1619912318

Payments from drug & device makers

$716in general payments, 2019–2025

Across 36 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$116
  • Harrow Eye, LLC$104
  • Alcon$99
  • Bausch & Lomb Americas Inc.$71
  • Kala Pharmaceuticals, Inc.$63
  • AbbVie$58
  • plus $204 from 7 others

What the payments were for

  • Food & beverage$716100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$716 in reported general payments places this provider in the 25th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$160,875
Medicare patients
541
Services billed
1,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost109$58,042
RestasisCyclosporine34$30,898
IlevroNepafenac36$13,693
Bromfenac Sodium72$13,195
VyzultaLatanoprostene Bunod11$12,481
Restasis MultidoseCyclosporine16$9,825
RocklatanNetarsudil Mesylat/Latanoprost25$9,042
SimbrinzaBrinzolamide/Brimonidine Tart22$8,634
Prednisolone Acetate241$7,432
RhopressaNetarsudil Mesylate13$7,202
Alphagan PBrimonidine Tartrate14$7,190
Latanoprost387$5,924
MoxifloxacinMoxifloxacin Hcl230$5,388
ProlensaBromfenac Sodium14$4,850
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$3,586

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose, Alphagan P$58$105,956173 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$57$16,24438 claims
Bausch & Lomb Americas Inc.Vyzulta$71$12,48111 claims
AlconSimbrinza$99$8,63422 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$19$4,85014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →